Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Nov 2019 Planned End Date changed from 1 Aug 2022 to 20 Jul 2020.
- 25 Nov 2019 Planned primary completion date changed from 1 Aug 2022 to 20 Jul 2020.
- 04 Jun 2019 Results (n=3) assessing safety and efficacy of nivolumab, cabiralizumab, and stereotactic body radiotherapy (SBRT) in locally advanced unresectable pancreatic cancer patients, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.